hIL-7-hyFc induces the expansion of circulating CD8⁺and CD4⁺T cells with cell proliferation and upregulated Bcl-2 expression. (A) Study design, showing the injection route and dose, and the PBMC collection schedule. The absolute counts of lymphocyte subsets were obtained from the complete blood counts using the ALC and flow cytometry–based frequencies. (B) FC in absolute counts of CD3⁺ cells over baseline, which was an average value on a day before and the day of administration. The data set for this graph was adapted from a previous report.²³ (C) Absolute cell number of CD8⁺ T cells (bottom) and FC over baseline in CD8⁺ T-cell number (top). (D) Absolute cell number of CD4⁺ T cells (bottom) and FC over baseline in CD4⁺ T-cell number (top). (E-G) Expression changes of CD127, Ki-67, and Bcl-2 among CD8⁺ and CD4⁺ T cells after hIL-7-hyFc administration, as analyzed by flow cytometry. Plots show expression levels on days 0 and 21 and the maximum change time point. (E) Frequencies of CD127⁺ cells among CD8⁺ and CD4⁺ T cells. (F) Frequencies of Ki-67⁺ cells among CD8⁺ and CD4⁺ T cells. (G) Bcl-2 expression as gMFI among CD8⁺ and CD4⁺ T cells. Plot shows the mean values (± standard error of the mean) for each cohort at the indicated time points. P values of FC over baseline in panels B to D represent comparisons between cohorts by two-way RM ANOVA with Geisser-Greenhouse correction. Green, red, and blue asterisks indicate P values between an indicated group and the placebo group. Black asterisks next to the graphs indicate P values between 2 groups indicated. Black asterisks above the graphs indicate P values between the value of each time point to that of baseline (day 0) by a Wilcoxon matched-pairs signed-rank test. ∗∗∗P < .001, ∗∗P < .01, ∗P < .05.